远红外辐射对血液透析患者动静脉内瘘干预比例的影响:一项随机试验
该多中心随机对照试验纳入115例使用功能良好动静脉内瘘的维持性血液透析患者,比较每次透析时远红外辐射40分钟持续1年与无远红外辐射的效果。结果显示,12个月时两组至少接受一次干预的患者比例无显著差异(19% vs 28%,P=0.25),首次干预时间、血栓形成比例及通路流量变化亦无差异。研究不支持远红外辐射改善动静脉内瘘存活。
要点
- 远红外辐射未降低12个月内动静脉内瘘干预比例(19% vs 28%,P=0.25)。
- 两组血栓形成比例、首次干预时间及通路流量变化均无显著差异。
- 结果不支持既往血管通路指南中远红外辐射改善内瘘存活的提议。
核心结论
- 为期12个月的远红外辐射治疗未影响动静脉内瘘的总体通畅性。
- 远红外辐射组与对照组在干预患者比例及所有次要终点上均无差异。
研究设计与样本
- 多中心随机对照试验,共随机分配115例患者至远红外辐射组(n=58)或对照组(n=57)。
- 纳入标准为接受慢性血液透析且动静脉内瘘功能良好的患者。
- 远红外辐射组在每次血液透析时对动静脉内瘘上方皮肤进行40分钟远红外辐射,持续1年。
主要发现
- 12个月时至少接受一次干预(血栓切除术或经皮腔内血管成形术)的患者比例:远红外辐射组19%,对照组28%,P=0.25。
- 动静脉内瘘血栓形成比例:远红外辐射组5%,对照组3%,P=0.26。
- 首次干预时间:远红外辐射组164天(四分位距86-272),对照组127天(四分位距44-164),P=0.26。
- 通路流量变化两组间无差异(P=0.86)。
临床怎么用
- 不应基于改善内瘘存活的目的常规使用远红外辐射治疗。
- 需重新评估既往血管通路指南中关于远红外辐射的建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Far infrared radiation did not improve the proportion of interventions in arteriovenous fistulas in patients on hemodialysis after 12 months of treatment. No difference was seen between treatment groups in time to intervention, number of thrombosed fistulas, and change in access flow. This study does not support the effect of far infrared radiation on fistula survival as proposed in previous vascular access guidelines. INTRODUCTION: In patients on hemodialysis, the risk of arteriovenous fistula (AVF) failure is unacceptably high. Up to 67% of AVFs need an intervention within 1 year after placement. There are no effective treatments to prolong AVF longevity. Far infrared radiation (FIR) treatment has been suggested to enhance AVF survival. The present trial investigated the effect of FIR on the proportion of interventions in the AVF. METHODS: In a multicenter, randomized, controlled trial, patients were allocated to receive FIR treatment or no FIR. Eligible patients were patients on chronic hemodialysis with a well-functioning AVF. The FIR group received FIR above the skin of their AVF for 40 minutes at every hemodialysis session for 1 year. The primary outcome was the difference in the proportion of patients with at least one intervention (thrombectomy or percutaneous transluminal angioplasty) after 12 months. The chi-squared test analyzed the difference. Secondary outcomes included differences in the number of thrombosed AVFs, intervention rate, access flow at various time points, and time to first intervention between groups. RESULTS: A total of 115 patients were randomized to the FIR group ( n =58) or the control group ( n =57). Baseline characteristics were similar in both groups. There was no significant difference in the proportion of patients with interventions between the FIR and control groups (19% versus 28%, P = 0.25) or in the proportion with thrombosed AVFs (5% versus 3%, P = 0.26). Time to first intervention was 164 (interquartile range, 86-272) days in the FIR group and 127 (interquartile range, 44-164) days in the control group ( P = 0.26). No differences in the change of access flow occurred ( P = 0.86). CONCLUSION: During 12 months of treatment, FIR did not affect the overall patency of the AVF. No difference was found in the number of patients with interventions or in any of the secondary endpoints (Clinicaltrials.gov: NCT04011072 ). CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Clinicaltrials.gov: NCT04011072.
引用
- Lindhard K, Hansen HP, Gliese K, et al. Effect of Far Infrared Radiation on the Proportion of Interventions in Arteriovenous Fistulas in Patients on Hemodialysis: A Randomized Trial. Clin J Am Soc Nephrol. 2026. PMID: 42284099. doi:10.2215/CJN.0000001079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。